Literature DB >> 10669158

Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression.

T L Yang1, J Cui, J M Taylor, A Yang, S B Gruber, D Ginsburg.   

Abstract

Factor V (FV) is a critical component of the coagulation cascade. FV-deficient patients suffer moderate to severe bleeding, though residual FV activity is detectable in nearly all cases. In contrast, FV-deficient mice die either during mid-embryogenesis, or of massive perinatal hemorrhage. In order to examine the requirements for FV in murine embryogenesis and hemostasis, we generated transgenic mouse lines expressing a Fv minigene under control of either the tissue-specific albumin (Malb) or rat platelet factor 4 (Rpf4) promoter. A total of 12 Malb and 3 Rpf4 lines were analyzed. Though expression in the target tissue was detectable in most lines by RT-PCR, only low levels of transgene expression were achieved (<3% of endogenous Fv in all lines). Despite a low level of Fv transgene expression, rescue of the lethal Fv-/- phenotype was observed with one of the Malb transgenic (Tg+) lines. However, rescue appeared to be incomplete with continued loss of >1/2 of expected Tg+,Fv-/- mice in early embryogenesis. Rescued Tg+,Fv-/- mice have undetectable FV (<0.1%) in both plasma and platelet compartments, but survive the perinatal period and mature to adulthood without spontaneous hemorrhage. We conclude that FV present at <0.1% is sufficient to support postnatal survival. Failure of the Malb transgene to rescue the midembryonic block suggests that FV expression is required during mammalian development at higher levels or with a different tissue-specific or temporal pattern. Taken together, these data may explain the observation of residual FV activity in most human FV-deficient patients due to early embryonic lethality in those absolutely deficient, and suggest that minimal levels of FV expression, below the level of detection, also may be sufficient to support survival in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669158

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Conditional overexpression of transgenes in megakaryocytes and platelets in vivo.

Authors:  Hao G Nguyen; Guangyao Yu; Maria Makitalo; Dan Yang; Hou-Xiang Xie; Matthew R Jones; Katya Ravid
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

2.  A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice.

Authors:  Michael F Bode; Nigel Mackman
Journal:  Thromb Res       Date:  2016-08-22       Impact factor: 3.944

3.  Polyphosphate accelerates factor V activation by factor XIa.

Authors:  Sharon H Choi; Stephanie A Smith; James H Morrissey
Journal:  Thromb Haemost       Date:  2014-10-23       Impact factor: 5.249

4.  Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis.

Authors:  Angela C Weyand; Steve J Grzegorski; Megan S Rost; Kari I Lavik; Allison C Ferguson; Marzia Menegatti; Catherine E Richter; Rosanna Asselta; Stefano Duga; Flora Peyvandi; Jordan A Shavit
Journal:  Blood Adv       Date:  2019-06-11

5.  Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction.

Authors:  R Pawlinski; A Fernandes; B Kehrle; B Pedersen; G Parry; J Erlich; R Pyo; D Gutstein; J Zhang; F Castellino; E Melis; P Carmeliet; G Baretton; T Luther; M Taubman; E Rosen; N Mackman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

6.  Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase.

Authors:  Aihua Zhu; Hongmin Sun; Richard M Raymond; Barbara C Furie; Bruce Furie; Mila Bronstein; Randal J Kaufman; Randal Westrick; David Ginsburg
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

7.  Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression.

Authors:  Yusuke Inoue; Luanne L Peters; Sun Hee Yim; Junko Inoue; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

8.  Identification of four novel mutations in F5 associated with congenital factor V deficiency.

Authors:  Sachiko Kanaji; Taisuke Kanaji; Miho Honda; Sachie Nakazato; Kazuo Wakayama; Yoshitomi Tabata; Shoichiro Shibata; Hisashi Gondo; Ikuko Nakamura; Koichi Node; Masanori Miura; Masaharu Miyahara; Takashi Okamura; Fumio Nagumo; Shoichiro Ohta; Kenji Izuhara
Journal:  Int J Hematol       Date:  2008-12-04       Impact factor: 2.490

9.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

10.  Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency.

Authors:  Keiko Shinozawa; Kagehiro Amano; Takashi Suzuki; Asashi Tanaka; Kenji Iijima; Hoyu Takahashi; Hiroshi Inaba; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.